On August 31, HANSOH PHARMA fell 3.16% in regular trading, trading at HK$35.20 per share, with turnover of approximately HK$105 million. The decline reflects a continuation of post-earnings profit-taking combined with broad-based pharmaceutical sector weakness.
The company had surged over 16% on August 27 after reporting stronger-than-expected interim results, including revenue of RMB 8.304 billion (up 11.7% YoY), attributable profit of RMB 4.258 billion (up 35.8% YoY), and innovative drug revenue reaching RMB 7.092 billion, accounting for a record 85.4% of total revenue. However, the stock has retreated in subsequent sessions as market participants locked in gains. Some analysts noted that the current valuation already reflects optimistic expectations, while upcoming sales expense expansion tied to new product launches such as HS-20093 and olatorepatide, as well as potential pricing pressure from national reimbursement negotiations, could constrain near-term profit margins.
The broader pharmaceuticals sector compounded the selling pressure on the day, with Luye Pharma down 7.98%, CSPC Pharmaceutical down 3.20%, SBP Group down 2.95%, and Hengrui Medicine down 2.04%, reflecting sector-wide weakness that further weighed on sentiment.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
